Revelation Biosciences (NASDAQ:REVB) Releases Earnings Results, Misses Expectations By $1.56 EPS

Posted by Tammy Falkenburg on May 9th, 2026

Revelation Biosciences (NASDAQ:REVB – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($2.71) EPS for the quarter, missing analysts’ consensus estimates of ($1.15) by ($1.56), FiscalAI reports.

Revelation Biosciences Stock Performance

REVB stock traded down $0.06 during mid-day trading on Friday, hitting $0.96. The company had a trading volume of 224,262 shares, compared to its average volume of 76,426. The firm has a market cap of $3.57 million, a PE ratio of -0.02 and a beta of -0.14. Revelation Biosciences has a 12 month low of $0.95 and a 12 month high of $40.08. The stock’s fifty day moving average price is $1.20 and its two-hundred day moving average price is $2.60.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a research note on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Sell”.

Read Our Latest Analysis on Revelation Biosciences

Institutional Investors Weigh In On Revelation Biosciences

A hedge fund recently bought a new stake in Revelation Biosciences stock. Geode Capital Management LLC purchased a new position in Revelation Biosciences, Inc. (NASDAQ:REVB – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned 2.15% of Revelation Biosciences at the end of the most recent quarter. Institutional investors own 12.80% of the company’s stock.

Revelation Biosciences Company Profile

(Get Free Report)

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.